RUA Life Sciences (FRA:AOHA) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:AOHA RUA Life Sciences PLC FRA:AOHA
46 GF Score
Price €0.29
GF Value €0.15
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is RUA Life Sciences Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of RUA Life Sciences is: High Risk: High uncertainty with risk-return tradeoff.

RUA Life Sciences  (FRA:AOHA) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

RUA Life Sciences Risk Assessment Related Terms

FRA:AOHA vs ABT, SYK, MDT: Risk Assessment Comparison

For the Medical Devices subindustry, RUA Life Sciences's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RUA Life Sciences Risk Assessment vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, RUA Life Sciences's Risk Assessment distribution charts can be found below:

* The bar in red indicates where RUA Life Sciences's Risk Assessment falls into.


FRA:AOHA
46GF Score
RUA Life Sciences PLC FRA:AOHA
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is RUA Life Sciences (FRA:AOHA) Overvalued in 2026?

Based on GuruFocus' analysis, RUA Life Sciences stock appears to be overvalued. The current stock price of €0.29 is trading 92% above its estimated GF Value™ of €0.15. GuruFocus considers RUA Life Sciences to be Significantly Overvalued.

Key valuation signals for FRA:AOHA:

  • Risk Assessment:
  • GF Value™: €0.15 vs. price of €0.29 (92% above fair value)
  • GF Score™: 46/100 with 5 warning signs

No single metric tells the full story. See the FRA:AOHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RUA Life Sciences Business Description

Other Exchanges RUA:UK
Address 2 Drummond Crescent, Scotland, Irvine, Ayrshire, GBR, KA11 5AN
RUA Life Sciences PLC is engaged in the contract design and manufacture of medical devices, exploiting the value of its IP and know-how, and developing cardiovascular devices. The Biomaterials segment is a licensor of Elast-Eon polymers to the medical device industry. The Medical Devices & Components segment is an end-to-end contract developer and manufacturer of medical devices and an implantable fabric specialist, which generates maximum revenue. The Vascular segment focuses on the development and commercialisation of the Group's Elast-Eon sealed Vascular Graft products. The Structural Heart segment focuses on the development of the Group's tri-leaflet polymeric heart valves. Geographically, it operates in Europe, North America, Middle East, Asia Pacific, and Africa.
46GF Score

Get the complete analysis for FRA:AOHA

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.29
Price
€0.15
GF Value